AI in Medical Diagnostics Market

Overview

The global AI in Medical Diagnostics Market was valued at USD 2.2 billion in 2025 and is projected to reach USD 13.8 billion by 2034, growing at a CAGR of 22.6% during the forecast period (2026-2034). The market is driven by the rising global burden of chronic and infectious diseases, an acute shortage of trained radiologists and pathologists, and the accelerating pace of regulatory clearances for artificial intelligence tools used in clinical diagnostic settings. The market is shifting from conventional, narrow, single-task algorithms trained to detect one specific abnormality toward multimodal and foundation-model-based platforms capable of triaging dozens of conditions from a single imaging study or combining imaging, laboratory, and clinical-note data within one workflow. Diagnostic vendors are moving away from standalone software sold per indication and toward subscription-based operating systems that plug directly into hospital picture archiving and laboratory information systems. Government initiatives such as the United Kingdom's AI Diagnostic Fund, which has committed close to GBP 30 million to extend AI-assisted chest X-ray analysis to every NHS trust in England by 2029, and the United States Food and Drug Administration's authorization of a record 331 artificial intelligence and machine learning enabled medical devices in 2025, are reinforcing institutional confidence in clinical AI. Complementary public programs in the European Union, India, and Japan supporting digital health infrastructure, algorithm validation, and reimbursement pathways are further encouraging hospitals and diagnostic networks to formalize AI procurement rather than rely on isolated pilot projects. By region, North America held the largest share of the AI in Medical Diagnostics Market in 2025, supported by dense concentrations of academic medical centers, an established FDA clearance pathway, and early reimbursement precedent. Asia Pacific is expected to be the fastest-growing region during the forecast period, driven by expanding diagnostic imaging infrastructure, rising screening volumes, and strong government-backed digital health programs across China, India, and Japan.

Market Size & Share

Market Dynamics

KEY MARKET TREND

Multimodal, Foundation-Model-Based AI Platforms Emerging as a Transformational Trend

• Diagnostic AI vendors are moving beyond single-indication algorithms toward foundation-model platforms capable of screening a single CT or X-ray study for dozens of acute findings at once. This consolidation reduces the number of point solutions a hospital must validate, procure, and maintain, while giving radiology and emergency departments a broader safety net across high-volume imaging queues.
• Vendors are combining computer vision with natural language processing so that imaging findings, laboratory values, and physician notes can be interpreted together rather than in isolated silos. This multimodal approach improves the contextual accuracy of triage decisions and supports more consistent structured reporting, which in turn shortens the time between image acquisition and a clinician-ready diagnostic summary.
• Large imaging equipment manufacturers are embedding AI directly into scanners and enterprise imaging platforms, while independent AI-native firms are competing on the breadth of FDA-cleared indications and integration speed with hospital IT systems. This is pushing consolidation among smaller point-solution vendors and encouraging strategic partnerships between medical device incumbents and specialized software developers to avoid losing shelf space in radiology departments.
• According to the US FDA's official AI and Machine Learning Enabled Medical Device List, cumulative authorizations reached approximately 1,451 devices by the end of 2025, with radiology accounting for close to 76 percent of all listed devices.

KEY MARKET DRIVER

Rising Burden of Chronic Diseases and Shortage of Diagnostic Specialists is the Key Driver

• Health systems worldwide are contending with a sustained rise in cancer, cardiovascular disease, and neurological disorders that require timely and accurate diagnostic interpretation. AI-enabled triage and detection tools help radiology and pathology departments manage growing case volumes without a proportional increase in specialist headcount, directly supporting faster turnaround for time-sensitive conditions such as stroke and lung cancer.
• A persistent global shortage of radiologists and pathologists, particularly outside major metropolitan centers, is widening the gap between imaging and laboratory test volumes and the specialists available to interpret them. AI-assisted pre-screening and worklist prioritization allow existing specialists to focus their attention on the most urgent or complex cases first, reducing the risk of delayed diagnosis.
• Expanding electronic health record adoption and cloud-based picture archiving systems are giving diagnostic AI tools structured, machine-readable access to the imaging and clinical data they need to function at scale. This digital foundation is lowering the integration barrier for hospitals that previously lacked the infrastructure to deploy AI diagnostic software beyond isolated pilot studies.
• The World Health Organization reports that noncommunicable diseases, including cardiovascular disease, cancer, chronic respiratory disease, and diabetes, caused at least 43 million deaths in 2021, equivalent to roughly three-quarters of all non-pandemic-related deaths globally.

KEY MARKET OPPORTUNITY

Expansion of AI-Enabled Point-of-Care and Decentralized Diagnostics Creates Significant Market Opportunity

• Compact, AI-powered imaging devices are extending diagnostic capability beyond hospital radiology suites into primary care clinics, pharmacies, and community health programs. This decentralization allows conditions such as diabetic retinopathy, cardiovascular risk, and early-stage cancer to be screened closer to where patients already seek routine care, reducing dependence on scarce specialist appointments.
• Emerging markets with limited access to trained specialists represent a substantial untapped opportunity for AI diagnostic tools that can operate with minimal operator training and lower infrastructure requirements. Vendors that design low-cost, portable, and offline-capable diagnostic devices are positioned to capture demand in regions where traditional imaging and laboratory infrastructure remains sparse.
• As-a-service and subscription-based commercial models are lowering the upfront cost barrier for smaller hospitals and diagnostic chains to adopt AI tools that were previously affordable only to large academic institutions. This shift toward operating-expense based procurement is expected to widen the addressable customer base for diagnostic AI vendors over the forecast period.
• Identifeye HEALTH commercially launched its FDA-registered, AI-powered retinal screening platform designed for use by nurses and medical assistants in primary care and community settings without requiring an eye-care specialist. 

AI in Medical Devices Market Size, 2025-2034 (USD Million)

Segmentation Analysis

Analysis by Component

The software segment held the largest share of the AI in Medical Diagnostics Market in 2025, supported by its central role in interpreting medical images, laboratory data, and genomic sequences across radiology, pathology, cardiology, and neurology workflows. Hospitals and diagnostic laboratories are prioritizing software investment because algorithms can be updated, retrained, and scaled across multiple facilities without the recurring capital expense associated with new imaging hardware. Continued growth in FDA and CE-marked software clearances, expanding cloud-based deployment options, and rising demand for structured, auditable diagnostic reporting are reinforcing software's position as the primary revenue-generating component. Leading medical device manufacturers and AI-native vendors alike continue to concentrate the bulk of their research and development spending on software-based diagnostic algorithms rather than dedicated hardware.

Services are projected to register the fastest CAGR within the component segment during the forecast period, driven by rising demand for algorithm deployment support, workflow integration, staff training, and ongoing model maintenance as hospitals move AI diagnostic tools from pilot programs into routine clinical use. Health systems increasingly rely on managed and cloud-hosted service arrangements to handle data security, interoperability with existing radiology and laboratory information systems, and continuous performance monitoring required under predetermined change control frameworks. The growth of telehealth and remote diagnostic review is further expanding demand for subscription-based analytics and consulting services that support distributed and multi-site diagnostic networks. Because services can scale independent of new device purchases, vendors are prioritizing service-based revenue streams as a durable growth lever.

Component categories include

• Software (Dominating Segment)
• Services (Highest CAGR Segment)
• Hardware

Analysis by Technology

Machine learning holds the largest share of the AI in Medical Diagnostics Market by technology, forming the analytical foundation for the majority of commercially deployed diagnostic algorithms across imaging, pathology, and laboratory applications. Its dominance is reinforced by a mature base of validated training datasets, a growing library of FDA-cleared machine learning models, and broad familiarity among radiologists and pathologists with how these systems generate and explain their outputs. Vendors continue to refine machine learning pipelines to improve sensitivity and specificity across diverse patient populations, supporting wider clinical acceptance. The technology's ability to be retrained on new data under regulator-approved change control plans further cements its position as the primary technology underpinning diagnostic AI products.

Computer vision is expected to grow at the fastest CAGR among diagnostic AI technologies during the forecast period, propelled by expanding use in radiology, digital pathology, dermatology, and ophthalmology, where visual pattern recognition directly supports abnormality detection and quantification. Advances in image segmentation and real-time analysis are enabling computer vision systems to process whole-slide pathology images and multi-slice imaging studies with greater speed and consistency than earlier generations of software. Rising deployment of point-of-care imaging devices, including portable ultrasound and retinal cameras, is further accelerating demand for embedded computer vision algorithms capable of operating outside traditional hospital radiology departments. This expanding application base is drawing sustained investment from both established imaging manufacturers and specialized AI developers.

Technology categories include

• Machine Learning (Dominating Segment)
• Computer Vision (Highest CAGR Segment)
• Deep Learning
• Natural Language Processing
• Other Technologies

Analysis by Application

Neurology held for the largest share of the market by application, reflecting the growing prevalence of neurological disorders such as stroke, Alzheimer's disease, and Parkinson's disease that require rapid and precise imaging interpretation. AI-based tools that automatically flag large-vessel occlusions, intracranial hemorrhage, and early neurodegenerative changes are widely credited with shortening the time between scan acquisition and treatment decisions in time-critical stroke care pathways. Growing adoption of AI-assisted brain MRI and CT analysis across stroke centers and specialized neurology practices continues to reinforce this segment's leadership. Ongoing clinical validation studies and expanding regulatory clearances for neurology-focused algorithms are further consolidating demand from hospital neurology and emergency departments.

Oncology is projected to register the fastest CAGR among application segments, supported by the rising global cancer burden and the increasing use of AI to support early detection, tumor characterization, and biomarker quantification across radiology and digital pathology. AI-powered image analysis tools are helping pathologists standardize the scoring of biomarkers used to guide treatment decisions, while AI-assisted mammography and lung-cancer screening are shortening the interval between imaging and diagnosis. Pharmaceutical companies are also incorporating AI pathology tools into clinical trial workflows to accelerate biomarker-driven drug development. This combination of clinical screening demand and pharmaceutical research use is expected to sustain oncology's rapid growth throughout the forecast period.

Application categories include

• Neurology (Dominating Segment)
• Oncology (Highest CAGR Segment)
• Radiology
• Cardiology
• Pathology
• Other Applications

Analysis by End User

Hospitals accounted for the largest share of the market by end user in 2025, supported by their high patient volumes, established radiology and pathology departments, and the infrastructure needed to integrate AI tools into existing picture archiving and laboratory information systems. Large hospital networks and academic medical centers are typically first to pilot and scale AI diagnostic tools because they have dedicated IT teams, established vendor relationships, and greater capital budgets for new technology. Hospitals also generate the diverse case volumes needed to validate algorithm performance across varied patient populations, reinforcing their central role in the ongoing clinical deployment of diagnostic AI.

Diagnostic imaging centers are projected to grow at the fastest CAGR among end users during the forecast period, as standalone imaging providers adopt AI-assisted triage and reporting tools to manage rising scan volumes without proportionally expanding radiologist staffing. These centers are increasingly positioned as high-throughput screening hubs for conditions such as breast cancer and cardiovascular disease, making rapid, AI-supported turnaround a competitive differentiator against hospital-based imaging departments. Growing outsourcing of teleradiology reporting to specialized imaging networks is further increasing demand for AI-based worklist prioritization and quality assurance tools. This trend is expected to accelerate as imaging centers seek to expand screening capacity within existing radiologist staffing levels.

End User categories include

• Hospitals (Dominating Segment)
• Diagnostic Imaging Centers (Highest CAGR Segment)
• Diagnostic Laboratories
• Other End Users

By Region

AI in Medical Diagnostics Market Share 2025 (by Region)

North America

50%

South America

xx%

Europe

xx%

Middle East Africa

xx%

Asia Pacific

22%

North America held for the largest share of the AI in Medical Diagnostics Market in 2025, led by the United States, where a mature FDA regulatory pathway, extensive academic medical center infrastructure, and established insurer reimbursement precedent for AI-assisted radiology and pathology services support rapid commercial adoption. The region benefits from a dense population of AI-native diagnostic companies, many of which are headquartered in the United States and Canada, alongside strong participation from global medical device manufacturers with established North American operations. Canada is seeing growing integration of AI tools into provincial imaging and screening programs, particularly for cancer and cardiovascular disease. Continued FDA authorization of new AI and machine learning enabled devices, combined with expanding private insurer coverage decisions, is expected to sustain North America's leadership through the forecast period.

Asia Pacific is projected to be the fastest-growing region in the AI in Medical Diagnostics Market during the forecast period, supported by rapid expansion of diagnostic imaging infrastructure and government-backed digital health programs across China, India, and Japan. China's large hospital network and domestic AI industry are driving rapid deployment of imaging-based screening tools, while India's diagnostic AI vendors are partnering with public health authorities to expand tuberculosis, diabetic retinopathy, and cancer screening into underserved regions. Japan continues to integrate AI diagnostic tools into its aging-population healthcare system, particularly for cardiology and oncology applications. Rising healthcare digitization, growing telemedicine adoption, and increasing venture investment in regional AI diagnostic startups are expected to sustain Asia Pacific's above-average growth rate throughout the forecast period.

Countries and Regions Covered

Asia-Pacific

• China (Largest Country Market)
• India (Fastest-Growing Country Market)
• Japan
• South Korea
• Rest of Asia-Pacific
  

North America

• United States (Largest Country Market)
• Canada
• Mexico
  

Europe

• Germany (Largest Country Market)
• France
• United Kingdom
• Italy
• Rest of Europe
  

Latin America

• Brazil (Largest Country Market)
• Chile (Fastest-Growing Country Market)
• Rest of Latin America
  

Middle East & Africa

• Saudi Arabia (Largest Country Market)
• United Arab Emirates (Fastest-Growing Country Market)
• Rest of Middle East & Africa

Market Share

The AI in Medical Diagnostics Market is fragmented, combining large, diversified medical device manufacturers with a broad base of specialized AI-native software developers. Established imaging companies compete primarily by embedding AI directly into their scanners and enterprise imaging platforms, while independent AI vendors differentiate through the breadth of their FDA-cleared indications and speed of integration with hospital IT systems. Key success factors include regulatory clearance depth, clinical validation evidence, and interoperability with existing picture archiving and laboratory information systems. Leading companies are prioritizing platform consolidation, geographic expansion into underserved markets, and strategic partnerships with hospital networks, diagnostic laboratories, and pharmaceutical companies to broaden their commercial footprint. Frequent licensing agreements, minority investments, and product co-development deals continue to shape competitive positioning across the industry.

Key Players

• Siemens Healthineers AG (Germany)
• GE HealthCare Technologies Inc. (United States)
• Koninklijke Philips N.V. (Netherlands)
• Canon Medical Systems Corporation (Japan)
• FUJIFILM Holdings Corporation (Japan)
• Aidoc Medical Ltd. (Israel)
• Viz.ai, Inc. (United States)
• PathAI, Inc. (United States)
• Tempus AI, Inc. (United States)
• Qure.ai Technologies Pvt. Ltd. (India)
• Nano-X Imaging Ltd. (Israel)
• Digital Diagnostics Inc. (United States)
• Butterfly Network, Inc. (United States)
• HeartFlow, Inc. (United States)
• Ibex Medical Analytics Ltd. (Israel)
• Lunit Inc. (South Korea)

Recent Market Developments

• In February 2025, NHS England launched the world's largest AI mammography trial, deploying five different AI systems to double-read approximately 462,000 of 700,000 planned screening studies across thirty imaging centres, testing whether AI can safely take on a share of breast cancer screening reads.
• In June 2025, PathAI received US FDA 510(k) clearance for its AISight Dx digital pathology image management platform for use in primary diagnosis, becoming one of the first digital pathology systems authorized with a Predetermined Change Control Plan that allows future feature updates without new regulatory submissions.
• In August 2025, HeartFlow completed its initial public offering on the Nasdaq under the ticker HTFL, raising approximately USD 364 million to expand commercial deployment of its AI-based coronary artery disease analysis platform across US hospital networks.
• In September 2025, HeartFlow received FDA 510(k) clearance for an updated version of its AI-based Plaque Analysis platform, showing a 21 percent improvement in plaque detection accuracy, with Cigna becoming the second national US insurer to add coverage for the service.

Frequently Asked Questions

Key Questions Answered

Request a Sample

1

What is AI in Medical Diagnostics?

2

What is the CAGR of the AI in Medical Diagnostics Market?

3

Which application leads the AI in Medical Diagnostics Market?

4

Which end user dominates the AI in Medical Diagnostics Market?

5

Which technology has the highest market share?

6

What are the latest trends in the AI in Medical Diagnostics Market?

7

Who are the end users of AI in Medical Diagnostics?

Why Choose IG Transformation

Speak to Analyst

Strong Industry Focus

Extensive Product Offerings

Customer Research Services

Robust Research Methodology

Comprehensive Reports

Latest Technological Developments

Value Chain Analysis

Potential Market Opportunities

Growth Dynamics

Quality Assurance

Post-sales Support

Regular Report Updates